Pfizer's talazoparib under review in U.S., EU

Pfizer Inc. (NYSE:PFE) said FDA accepted and granted Priority Review to its NDA for talazoparib (MDV3800) to treat germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. Its PDUFA date is in December.

EMA also accepted for review the company's MAA for the PARP inhibitor, Pfizer said...